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Immunoglobulin (Ig) isotype diversification by class
switch recombination (CSR) is an essential process
formounting a protective humoral immune response.
Ig CSR deficiencies in humans can result from an
intrinsic B cell defect; however, most of these
deficiencies are still molecularly undefined and
diagnosed as common variable immunodeficiency
(CVID). Here, we show that extracellular adenosine
critically contributes to CSR in human naive and
IgM memory B cells. In these cells, coordinate stim-
ulation of B cell receptor and toll-like receptors re-
sults in the release of ATP stored in Ca2+-sensitive
secretory vesicles. Plasma membrane ectonucleo-
side triphosphate diphosphohydrolase 1 CD39 and
ecto-50-nucleotidase CD73 hydrolyze ATP to adeno-
sine, which induces CSR in B cells in an autonomous
fashion. Notably, CVID patients with impaired class-
switched antibody responses are selectively defi-
cient in CD73 expression in B cells, suggesting that
CD73-dependent adenosine generation contributes
to the pathogenesis of this disease.
INTRODUCTION
Different cell types, including astrocytes, endothelial cells, plate-
lets, T cells, and monocytes, release ATP in the extracellular1824 Cell Reports 3, 1824–1831, June 27, 2013 ª2013 The Authorsspace as signaling molecules acting in a paracrine/autocrine
fashion (Corriden and Insel, 2010). Thus, transient and regulated
increases in extracellular ATP (eATP) are used for basic physio-
logical signaling in the nervous, vascular, and immune systems.
On the other hand, extracellular levels of ATP are controlled by
the expression of ectonucleotidases in the plasma membrane.
The rate-limiting step of the ectonucleotidase cascade for aden-
osine generation is represented by CD39 (E-NTPDase 1), an ec-
tonucleoside triphosphate diphosphohydrolase that hydrolyzes
ATP/UTP and ADP/UDP to the respective nucleoside (e.g.,
AMP). In turn, extracellular nucleoside monophosphates are
rapidly degraded to adenosine by plasma membrane ecto-50-
nucleotidase CD73 (Deaglio and Robson, 2011). More than 40
years ago, reduced CD73 activity was detected in lymphocytes
of patients suffering from immunodeficiency syndromes charac-
terized by hypo- and agammaglobulinemia (Johnson et al., 1977;
Edwards et al., 1978), but so far no functional relationship be-
tween B cell dysfunction and defects in enzymatic activity has
been defined.
RESULTS AND DISCUSSION
CD73 was originally used as a surface marker to identify individ-
ual B cell subsets at specific stages of differentiation (Resta
et al., 1998; Thompson and Ruedi, 1988). CD73 is expressed
in a subset of CD39+-naive (59.3% ± 8.1%), memory (60.9% ±
9.3%), and to a lesser extent germinal-center (12.9% ± 5.7%)
cells in tonsils and in a subset of CD39+-naive (45.1% ± 7.7%),
immunoglobulin M (IgM) memory (21.9% ± 5.4%), and switched
memory B (27+ 50.2% ± 5.1%, 27 41.7 ± 8.8) cells in the blood
A B
37
620.3
0.1
100
50
0
72
270.9
0.6
100
50
0
CD39+CD73+
CD39+CD73-
CD39- CD73-
CD39- CD73+
Naive IgM Memory
CD27 negative
Switch Memory
CD27 positive
Switch Memory
Germinal centreMemory
CD
 7
3
CD 39
Ig
G
/Ig
A
CD 27
CD
 3
8
CD 27
CD
 7
3
CD 39
IgM MemoryNaive
CD39+CD73+
CD39+CD73-
57
344.3
3.9
100
50
0
Naive
100
50
0
67
271.4
5.1
100
50
0
75
210.7
3.7
100
50
0
4.3
55
1.3
39
C D
E F
Peripheral blood
Tonsil 
R1
R2
R3
R1
R3R2
R1 R2
R3R4 R1 R2
R3 R4
CD 19
CD 19
0.2
1.197
0.9
2.9
2260
15
0.2
8.989
2.2
0.2
0.993
6.1
20
0
30
40
10
CpG
CpG CpG + anti-Ig CpG CpG + anti-Ig 
IgG/A secreting cells Cytokines secreting cells
Ig
G
/A
CFSE
4
0
2
6
8
4
0
6
2
CpG + anti-Ig 
2
0
3
1
** ***
IL-4 IL-13
PBMC
CD39+CD73-
CpG + anti-Ig 
+ CD40L
CpG + anti-Ig 
+ CD40L
+ CD40L
% % % %
3.6 2.8
2667
12 4.3
3054
***
Naive IgM Memory
IgM MemoryNaive
CD39+CD73+
**
100
50
0
60
334.1
2.6
CpG + anti-lg
Figure 1. CD39 and CD73 Expression in Human B Cells Correlates
with CSR
(A) Human mature B cell subsets in peripheral blood (lower panel) and tonsil
(upper panel) were identified by flow cytometry with a combination of mono-
clonal antibodies specific for CD19, CD27, IgG/IgA and CD19, CD38, and
CD27, respectively. Dot plots were electronically gated on CD19+ B cells to
identify the following subpopulations: R1, CD19+CD27IgG/IgA naive,
R2 CD19+CD27+IgG/IgA IgM memory, R3 CD19+CD27+IgG/IgA+ switch
memory B cells, R4 CD19+CD27IgG/IgA+ switchmemory B cells in peripheral
blood, and R1 CD19+CD38+CD27+ germinal center, R2 CD19+CD38CD27
naive, and R3 CD19+CD38CD27+ memory B cells in tonsil.
(B) Representative analysis of CD39 and CD73 expression in B cell subsets in
peripheral blood (upper panels) and tonsil (lower panels). Numbers reported in
dot plots indicate the percentage of cells within the quadrant. Bars showmean
C(Figures 1A and 1B). A detailed analysis of CD39 and CD73
expression in murine B cell subsets revealed the preferential
expression of CD73 in mature class-switched and germinal-
center B cells (Figure S1A).
To address whether the ATP-hydrolases CD39 and CD73
contribute to signals leading to B cell activation, we stimulated
naive and memory B cells purified on the basis of CD73 expres-
sion with anti-B cell receptor (anti-Ig) antibody, CD40L,
and CpG 2006 as the toll-like receptor 9 (TLR9) ligand.
CD39+CD73+-naive andmemory B cells did not display any sub-
stantial differences in proliferative activity with respect to
CD39+CD73 B cells (Figure S2A). However, the percentage
of naive and IgM memory B cells, which switched in vitro to
IgG or IgA, was enriched in the CD39+73+ fraction (Figure 1C).
Accordingly, the frequency of IgG or IgA secreting cells (ISCs)
as measured by enzyme-linked immunosorbent spot (ELISPOT)
assay was significantly higher in CD73+ cells (Figures 1D and
1E). Remarkably, class switch recombination (CSR) in response
to TLR9 stimulation was confined within the CD73-expressing
IgM memory B cells (Figures 1D and 1E). Tlr9 was expressed
to the same extent in CD39+CD73+ and CD39+CD73 memory
B cells (Figure S3B). Analysis of transcription factors involved
in late B cell development, revealed in IgM memory
CD39+CD73+ B cell subsets a significant increase in the expres-
sion of Xbp-1 (Figures S3C and S3D). Naive and IgM memory B
cell subsets coexpressing CD39 and CD73 were also analyzed
for the expression of surface markers involved in T cell costimu-
lation, B cell activation, and survival, and compared with CD39
single-positive B cells. Surface expression of CD180, a TLR ho-
molog that influences the sensitivity of naive as well as memory
B cells to stimulation via TLR9 and CD40L (Good et al., 2009),
was significantly increased in CD39+CD73+ with respect to
CD39-only B cells. In addition, BAFFR and TACI, which belong
to the tumor necrosis factor a (TNF-a) family, were increased
in both CD39+CD73+-naive and memory B cells (Figure S4).
We also evaluated whether mouse naive B cells coexpressing
CD39 and CD73 differentiated more efficiently to class-switched
ISC with respect to CD39 single-positive naive B cells. The
CD39+CD73+ fraction was enriched in cells, which switched
in vitro to IgG (LN cells) and to both IgG and IgA (PP cells).
Accordingly, the frequency of IgG or IgA ISCs measured by
ELISPOT assay was significantly higher in the CD73+ subset
(Figure S1B). CSR is induced by interleukin-4 (IL-4) and IL-13percentages of B cell subsets in normal donors according to the indicated
CD39 and CD73 phenotype; peripheral blood n = 10, tonsil n = 6.
(C) CFSE dilution and expression of surface IgG and IgA in CD39+73 (upper
row) and CD39+73+ (lower row) naive and IgM memory B cells after 6 days
stimulation with CpG 2006, anti-ig and CD40L or CpG 2006, or CpG 2006 and
anti-Ig, in the presence of IL-2.
(D) Representative pictures of IgG/IgA-secreting cells in ELISPOT assay.
(E) Statistics of IgG/IgA-secreting cells in ELISPOT assay after 6 days of
stimulation, expressed as percentage of live cells (open bars: CD39+CD73,
black bars: CD39+CD73+). Left panel: mean + SD, n = 10, *p = 0.0213; middle
panel: mean + SD, n = 2–4, **p = 0.000174; right panel: mean + SD, n = 8, *p =
0.032.
(F) Frequency of IL-4- and IL-13-secreting cells in the indicated subsets (open
bars: CD39+CD73; black bars: CD39+CD73+ cells) of CD19+27+ memory B
cells after 5 hr stimulation with CpG 2006, anti-Ig, and CD40L. IL-4: n = 9, **p <
0.008; IL-13: n = 9, **p < 0.0001.
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Figure 2. Storage and Release of ATP in Human B Cells
(A) Purified naive (left panel) and memory (middle panel) B cells, and EBV-LCL
(right panel) were labeled with quinacrine and DAPI and analyzed by confocal
microscopy.
(B) Subcellular fractionation of EBV-LCL on equilibrium sucrose gradient.
Luciferase assay for ATP content in each fraction, expressed as percentage of
luminescence. Western blot for Ti-VAMP, endobrevin, cellubrevin, and early
endosomal marker EEA1 on the isolated fractions.
(C) In dual-wavelength recording by TIRF microscopy, the laser beam was
tilted at a precise critical angle (q) to obtain total internal reflection at the glass-
cell interface (left panel). The dynamic scanner (Leica AM TIRF MC) precisely
positioned the laser beam and determined the exact penetration depth of the
evanescent field (EF). To confine the analysis to juxtamembrane regions of the
cells with high spatial resolution, we restricted the excitation and detection of
the fluorophores to 70–90 nm in depth. EBV-LCL cells transfected with TI-
Vamp RFP were incubated with Mant-ATP for 12 hr. In live experiments, Mant-
ATP (green) and TI-Vamp RFP (red) signals were imaged in sequential mode
under EF illumination (middle panel). Colocalization signals of the two fluo-
rophores, above background threshold, are shown as a binary image (white)
and superimposed onto fluorescent signals (right panel). The contribution of
Mant-ATP signal to the colocalization areas is expressed as percentage
(Manders’ M1 coefficient). A substantial portion of exogenous Mant-ATP co-
localized with TI-VAMP RFP in submembrane granules.
(D) EBV-LCL cells transfected with TI-Vamp RFP were incubated with quina-
crine at different times (5, 20, and 60 min). Quinacrine loaded into TI-Vamp-
positive vesicles is shown as colocalization signals (white) as in (C). Arrows
indicate the appearance of the colocalization signals at each investigated time.
(E) Live TIRF imaging of secretory events in EBV-LCL cells incubated with
quinacrine for 60 min. Quinacrine displays marked pH dependence and accu-
mulates in a self-quenched state inside acidic vesicles. Exocytosis is revealed
by the occurrence of fluorescencedequenching (light flash) caused by the rapid
increase in pH upon diffusion of quinacrine to the extracellular medium. Indi-
vidual secretory events were analyzed in basal conditions and upon stimulation
with anti-ig. Graphics below show changes of fluorescence intensity (FI) in
selected regions surrounding vesicles exocytosis (red circles, 1–3). Only when
quinacrine fluorescence increased and then declined below the basal level was
the event counted as a secretory event. To prevent photobleaching and
phototoxicityof thesample, TIRF imageswereacquired foronly40msat250ms
intervals. Light was filtered with dual-band-filter sets and fluorescence images
were visualized using a CCD camera. The scale bar represents 1 mm.
(F) Live Ca2+ TIRF imaging of secretory events in EBV-LCL (upper panel) and B
cells (lower panel) incubatedwith quinacrine and X-rhod for 60min. Changes in
X-rhod fluorescence intensity, revealing Ca2+ levels, were analyzed in regions
(circle and concentric annulus) surrounding quinacrine-labeled vesicles in
basal conditions and upon stimulation with anti-ig. Graphics on the right show
changes of quinacrine and X-rhod fluorescence intensity in the regions of in-
terest. The scale bar represents 1 mm.
(G) ATP content in the supernatants of human B cells stimulated in vitro with
CpG 2006 and anti-Ig at different time points by luciferase assay. Measure-
ments were performed with or without ARL, an inhibitor of the ectonucleoti-
dases CD39 and CD73. Mean ± SD, n = 4.
1826 Cell Reports 3, 1824–1831, June 27, 2013 ª2013 The Authors(Dunnick et al., 2011; Iwata et al., 2011), and stimulation of B
cells determined an increase in IL-4- and IL-13-secreting cells
in the CD73+ memory pool (Figure 1F). Interestingly, purinergic
receptors, in particular adenosine receptors, were previously
shown to stimulate IL-4 secretion in mast cells (Ryzhov et al.,
2004). Staining of naive, memory B cells and Epstein-Barr virus
immortalized lymphoblastoid cell lines (EBV-LCL) with the fluo-
rescent, nucleotide-binding component quinacrine (Bodin and
Burnstock, 2001; Sorensen and Novak, 2001) revealed a punc-
tate staining indicative of ATP-filled vesicles (Figure 2A). Sub-
cellular fractionation of EBV-LCL on sucrose equilibrium gradi-
ents revealed, in addition to cytosolic ATP, a purine peak
that overlapped with the late endosomal and lysosomal
TI-VAMP/VAMP7, and to a much lesser extent with endobrevin
and the early and recycling endosomal cellubrevin, but not
with the early endosome marker EEA1 (Figure 2B; Stow et al.,
2006; Chaineau et al., 2009). These results indicate that ATP ac-
cumulates in late endosomal/lysosomal vesicular compartments
in human B cells. TI-VAMP is a vesicular SNARE protein that is
involved in lysosomal secretion and was shown to colocalize
with ATP in astrocytes (Verderio et al., 2012). In EBV-LCL ex-
pressing a TI-VAMP fused to red fluorescent protein (RFP), total
internal reflection fluorescence (TIRF) illumination revealed a
punctate pattern of TI-VAMP-RFP within submembrane regions,
suggesting the secretory nature of these vesicles (Figure 2C). In-
cubation of EBV-LCL expressing TI-VAMP-RFP with Mant-ATP,
a fluorescent nucleotide analog (Zhang et al., 2007), demon-
strated colocalization of Mant-ATP+ vesicles with TI-VAMP-
RFP+ submembrane puncta. Quinacrine labeling confirmed
that ATP-filled vesicles colocalized with TI-VAMP-RFP, with a
progressive increase over time (Figure 2D). Monitoring of fluo-
rescence changes in the submembrane compartment of primary
human B cells and EBV-LCL labeled with quinacrine upon stim-
ulation with anti-ig by time-lapse TIRF showed the appearance
of light flashes in different positions of the plasma membrane
at different times (33.0, 39.5, and 40.0 s), indicative of regulated
vesicular release (Figure 2E; Movie S1). To directly address the
role of TI-VAMP in ATP release by B cells, we used TI-VAMP-
deficient mice (Danglot et al., 2012). Murine B cells release
ATP with analogous kinetics of human B cells (Figure S5A).
However, TI-VAMP-deficient B lymphocytes displayed reduced
eATP levels upon stimulation with CpG, anti-Ig, anti-CD40, and
IL-21 (see below), and significantly reduced the frequency of IgG
and IgA ISC, suggesting that TI-VAMP is involved in ATP release
and CSR in B cells (Figures S5B and S5C). To define the stim-
ulus-secretion coupling mechanism, we investigated Ca2+
elevation during exocytosis (Figure 2F). Labeling of cells with
quinacrine and the Ca2+ indicator X-rhod, and imaging under
dual-wavelength TIRF before and after anti-Ig stimulation
showed Ca2+ events restricted to individual vesicles (circle)
and the surroundings of the fusion event (anulus). The submem-
brane Ca2+ ions were increased in strict spatial correlation with
the sites of vesicular fusion without lateral propagation of the
signal. The decrease of submembrane Ca2+ events once exocy-
tosis was completed, as compared with intracellular Ca2+ in
widefield imaging (Figures S2B and S2C), suggests that sub-
plasma membrane Ca2+ rises around the vesicular organelle
for the time required for exocytosis. This observation directly
proves that fast submembrane Ca2+ elevations are the events
that trigger ATP secretion in human B lymphocytes. Stimulation
of human B cells by anti-Ig and CpG led to ATP release in the
culture supernatant (Figure 2G). This increase was augmented
up to 6-fold by ARL67156, an efficient inhibitor of NTPDase1
and a partially effective inhibitor of CD73 (Le´vesque et al., 2007;
Karczewska et al., 2007), suggesting that CD39 and CD73 were
actively hydrolyzing the ATP that was released upon cell stimu-
lation. Thus, we measured adenosine in culture medium at
40 min after addition of exogenous ATP. Naive and memory
CD73+ B lymphocytes generated substantially more adenosine
than the CD73 counterpart (Figure 3A). Treatment of CD73+
cells with ARL67156 or a,b-methylene ADP (APCP), a specificCCD73 inhibitor, blocked adenosine generation and resulted in
accumulation of ATPandAMP, respectively (Figure 3A). The gen-
eration of adenosine by CD73+ cells results in stimulation of A2A
adenosine receptor subtype, which is expressed in B cells
(Junger, 2011) (Figure S3A). To determine whether extracellular
adenosine plays a role in CSR, we treated stimulated naive and
memoryCD73+BcellswithARL67156andadenosinedeaminase
(ADA), which degrades adenosine to inosine (Sauer and Aiuti,
2009). Both treatments significantly affected the generation of
isotype switched immunoglobulin of both naive and IgM mem-
ory B cells (Figure 3B). To directly address the role of adenosine
in Ig isotype switching, we incubated naive and memory cells
with adenosine in combination with anti-Ig, CpG 2006, and
CD40L. Adenosine significantly increased the differentiation of
naive and memory CD73 B cells to class-switched B cells (Fig-
ure 3B). These results suggest that adenosine generated by the
sequential activity of CD39 and CD73 on endogenous ATP
released upon B cell stimulation significantly contributes to
CSR. Remarkably, no differences in adenosine receptor expres-
sion were observed in CD39+CD73+ naive and memory B cells
compared with CD39+CD73 B subsets (Figure S3A). To directly
test the role of CD73 in CSR, we purified naive B cells from LNs
and PPs of Nt5e (CD73)-deficient mice. IL-21 induces CD73
expression in mouse Th17 lymphocytes (Chalmin et al., 2012),
and we observed the same effect in mouse naive B cells (Figures
S6A and S6B). Stimulation of naive B cells isolated from LNs
and PPs of Nt5e/ mice displayed a significant impairment in
their capacity to differentiate into class-switched IgG ISC after
in vitro stimulation with CpG and IL-21 or CpG, anti-Ig, and
IL-21 (Figure S6C). We then addressed whether expression of
CD73 and CD39was altered in a cohort of patients with common
variable immunodeficiency (CVID). CVID is the most common
clinically significant primary B cell immune deficiency and is
characterized by hypogammaglobulinemia, increased suscepti-
bility to infections, and autoimmune manifestations (Eibel et al.,
2010). Patients with CVID display reduced percentages of
switched memory B cells expressing IgG and IgA, and impaired
capacity to respond to antigen-dependent vaccination (Chovan-
cova et al., 2011; Foerster et al., 2010; van de Ven et al., 2011).
Remarkably, a significant decrease in cell-surface expression of
CD73 was observed in naive, IgM memory, and switched mem-
ory B cells of CVID patients compared with age-matched con-
trols (measured as the mean fluorescence intensity as well as
the percentage of CD73-expressing cells), whereas CD39
expression was comparable in all B cell subsets (Figures 4 and
S7). CD73 was undetectable by intracellular staining, indicating
that the absence of CD73 in the plasma membrane was not due
to a defect in the secretory pathway (Figure S8B). We then
induced CSR in vitro in CD19+ B cells by anti-Ig, bystander
T cell help, and CpG 2006. Although these culture conditions
promoted CSR in B cells from normal donors, they were
completely ineffective in B cells from a CVID patient with defec-
tive CD73 expression (Figures S8C and S8D). In contrast to con-
trol cells, CVID B cells failed to upregulate activation-induced
cytidine deaminase (AID) and BCL6, which were both strongly
transcribed in activated B cells from healthy donors (Figure S8E).
Because in addition to CSR, AID promotes somatic hyper-
mutation of Ig variable region genes, we analyzed VDJell Reports 3, 1824–1831, June 27, 2013 ª2013 The Authors 1827
Figure 3. Adenosine Generation in CSR
(A) Upper panel: HPLC analysis of ATP, ADP,
AMP, and adenosine content in the supernatants
of purified CD39+CD73 and CD39+CD73+ naive
and IgM memory B cells after addition of exoge-
nous ATP. Lower panel: The same analysis was
performed in the presence of ectonucleotidase
inhibitor ARL (red line) and the CD73 inhibitor
APCP (green line). One representative experiment
out of four is shown.
(B) Fold increase of IgG/IgA-secreting cells in
ELISPOT assay on purified naive and memory B
cells after 6 days of stimulation with CpG 2006/
anti-ig/CD40L and CpG 2006/anti-ig, respectively,
with or without ARL (100 mM; n = 4–5, **p = 0.0016,
**p = 0.0052), ADA (50 mM; n = 3–4, *p = 0.012,
**p = 0.0043), and adenosine (10 mM; n = 4–6, *p =
0.03, **p = 0.004).
(C) Schematic representation of the hypothesized
role played by CD73/adenosine in CSR in B cells.rearrangements and mutations in B cells from one CVID patient.
Whereas the rate of mutations in healthy donors was 5.3 per B
cell clone, an analysis of 75 individual B cell clones from the
CVID donor revealed a total of 83 somatic mutations corre-
sponding to 1.27mutations per clone (Figure S8A). These results
indicate that AID is less active in stimulated B cells from CVID
patients and this decrease in activity correlates with lack of
CD73. Restoration of AID activity and CSR in B cells from
CVID patients by stimulation with adenosine might be limited1828 Cell Reports 3, 1824–1831, June 27, 2013 ª2013 The Authorsby the coordinate regulation of CD73
and adenosine receptor responsiveness
in human B cells (Napieralski et al.,
2003). Altogether, these data show that
in human B cells, ATP is stored in secre-
tory vesicles that are released in a Ca2+-
sensitive fashion upon BCR stimulation.
We propose that CD73-dependent aden-
osine generation favors CSR, endowing
the B cell with an intrinsic control of differ-
entiation toward Ig class-switched
plasma cells.
EXPERIMENTAL PROCEDURES
Blood Samples and Patients
Blood samples from healthy donors and 24 CVID
patients were obtained from the Hospital Gaslini
Institute and the Centre of Chronic Immunodefi-
ciency, University Medical Centre. Informed writ-
ten consent was obtained from each individual
before participation, with approval from the inter-
nal ethics review board (239/99 and 78/2001).
Media and Reagents for B Cell Culture
Themedium used for B cell culture was RPMI 1640
(BioWhittaker) supplemented with 10% fetal
bovine serum (Defined; Hyclone) 2 mM GlutaMAX
(GIBCO), 10 mg/ml nonessential amino acids,
1mMpyruvate, 50U/ml penicillin, 50U/ml strepto-
mycin, 50 U/ml kanamycin (GIBCO), and 53 102M 2-mercaptoethanol (Sigma-Aldrich). The following chemical compounds
were used in the B cell culture system: ARL (100 mM), adenosine deaminase
(50 mM), and adenosine (10 mM) (Sigma-Aldrich).
Isolation of Human B Cell Subsets and Flow Cytometry Analysis
Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll-Hypaque
density centrifugation and stained with the following monoclonal antibodies:
CD19, CD73 (Becton Dickinson), CD27, CD39 (eBioscience), and surface
IgG and IgA (Jackson ImmunoResearch Laboratories). To perform functional
assays, CD19+ B cells were isolated with CD19 microbeads (Miltenyi Biotec)
CVID
8.6
29
5.3
57
0.2
7
3.1
89I
gG
/A
CD 27
CD
 7
3
CD 39
Ig
G
/A
CD 27
CD
 7
3
CD 39
3.2 50
414.6
0.1 0.9
8415
Healty Donor
B
C
A
15000
0
5000
10000
Naive
CD
 7
3 
M
FI
HD CVID
CD
 7
3 
M
FI
IgM Memory
HD CVID
*** **
Switch memory
CD
 7
3 
M
FI
HD
15000
0
5000
10000
CVID
20000 ***
15000
0
5000
10000
20000
25000
0
Naive
CD
 3
9 
M
FI
HD CVID
CD
 3
9 
M
FI
IgM Memory
HD CVID
n.s. n.s.
Switch memory
CD
 3
9 
M
FI
HD
30000
0
10000
CVID
20000
n.s.
15000
0
5000
10000
20000
25000
15000
5000
10000
20000
Figure 4. Selective CD73 Defect in B Cells from CVID Patients
(A) Flow cytometry for IgG/IgA, CD27 and CD39, and CD73 expression in electronically gated CD19+ B cells from a representative CVID patient and an age-
matched healthy donor.
(B) Mean fluorescent intensity (MFI) of CD73 in naive, IgMmemory, and switched memory B cells in CVID patients compared with age-matched controls (n = 11–
17, ***p = 0.0004, **p = 0.005, ***p < 0.0001).
(C) MFI of CD39 in naive, IgM memory, and switched memory B cells in CVID patients compared with age-matched controls (n = 11–23).according to the manufacturer’s instructions. Following staining for lineage
(CD3, CD14, and CD56; Beckman Coulter), CD19, CD27, surface IgG and
IgA, CD39, CD73, and naive and IgM memory B cells were sorted according
to the expression of CD73 and CD39 with the use of a cell sorter (FACSAria).
Murine B Cell Isolation and Flow Cytometry
Naive B lymphocytes were isolated from LNs of wild-type (WT), Vamp7/, and
Nt5e/ mice by negative enrichment with CD43 beads, followed by staining
for the lineage markers CD19, B220, IgG, and IgA, and then isolated by cell
sorting as CD19+ B220+ IgGIgA. PP B cells from WT, Vamp7/, and
Nt5e/ mice were directly stained with monoclonal antibodies specific for
CD19, B220, IgG, and IgA, and isolated as CD19+ B220+ IgGIgA.
Human and Murine Proliferation Assay
Human B cell subsets were labeled with 0.5 mM5-(and-6-)-carboxyfluorescein
diacetate, succinimidyl ester (CFSE) (Molecular Probes) for 8 min at room tem-
perature. Purified B cells (2–53 104 cells) were activated in 96-well flat-bottom
plates with the following stimuli: (1) 2.5 mg/ml CpG oligodeoxynucleotide 2006
(50-tcgtcgttttgtcgttttgtcgtt-30; TIB Molbiol), (2) 2.5 mg/ml F(ab0)2 anti-humanCIgM/IgA/IgG (Jackson ImmunoResearch Laboratories), (3) megaCD40L
12 ng/ml (Alexis), and (4) 2000 U/ml IL-2 (Proleukin; Chiron). The proliferation
profile of propidium-iodide-negative viable CD19-positive cells was analyzed
at day 4 of culture. To allow a direct quantitative comparison of B cell prolifer-
ation in the different conditions, fluorescence-activated cell sorting (FACS)
acquisitions were standardized by a fixed number of calibration beads (BD
Biosciences). Purified murine B lymphocytes were labeled with CellTracker
Violet (Molecular Probes) and stimulated in vitro in 96-well flat-bottom plates
with (1) 2.5 mg/ml CpG oligodeoxinucleotides 1826 (50-tccatgacgttcctga
cgtt-30; Microsynth), (2) 2.5 mg/ml anti-Ig M (Jackson ImmunoResearch Labo-
ratories), (3) 10 ng/ml or 20 ng/ml of IL-21 (for PP and LN, respectively; R&D
Systems), and (4) IL-2 100 UI/ml (Proleukin; Chiron).
ELISPOT
Plasma cells secreting IgG, IgM, or IgA were detected using an ELISPOT
assay. Briefly, 96-well plates (Millipore; Billerica) were coated with 10 mg/ml
purified goat anti-human IgG or IgA or IgM (Southern Biotechnologies). After
washing and blocking with 1% BSA in PBS for 30 min, serial dilutions of
cultured B cells were added and incubated overnight at 37C. The platesell Reports 3, 1824–1831, June 27, 2013 ª2013 The Authors 1829
were washed and incubated with isotype-specific, biotin-conjugated second-
ary antibodies, followed by streptavidin-HRP (Sigma-Aldrich). The assay was
developed with AEC (Sigma-Aldrich).
Intracellular Cytokine Secretion Analysis of Human B Cell Subsets
Peripheral B cells were enriched from PBMCs from healthy donors with CD20
microbeads (Miltenyi). B cells were cultured with the following stimuli: Cpg
(2.5 mg/ml), anti-Ig (2.5 ug/ml), IL2 (2000 U/ml), megaCD40L (12 ng/ml), BFA
(10 mg/ml), ionomycin (1 mg/ml), and phorbol 12-myristate 13-acetate (PMA;
50 ng/ml) for 5 hr (all from Sigma-Aldrich). Cells were stained for cell-surface
CD19, CD27, CD39, and CD73, and cytoplasmic expression of IL-4 or IL-13
according to the intracellular staining protocol for the Cytofix/Cytoperm kit
(BD Bisciences).
Subcellular Fractionation and Immunoblotting
EBV-B cell line were diluted 1:4 in homogenization buffer (10 mM HEPES-
KOH, pH 7.4, 250 mM sucrose, 1 mM Mg acetate, 0.5 mM phenylmethylsul-
fonyl fluoride, 2 mg/ml pepstatin, 10 mg/ml aprotinin). The cells were homo-
genized using a cell cracker (European Molecular Biology Laboratory)
and centrifuged at 1,000 3 g for 10 min to prepare the postnuclear superna-
tant. The supernatant was loaded onto 0.4–1.8 M sucrose gradient and spun
in a 41 SW rotor (Beckman Instruments) at 25,000 rpm for 18 hr. Fractions
(1 ml) were collected and analyzed by SDS-PAGE followed by western
blotting.
Bioluminescence Assay to Measure ATP
For ATP measurement, CD19-positive human B cells were isolated from buffy
coats of healthy donors and stimulated in vitro with 2.5 mg/ml CpG 2006 and
2.5 mg/ml F(ab0)2 anti-human IgM/IgA/IgG with or without 100 mM ARL, at
105 cells/well in 96-well round-bottom plates with a transwell on top. Superna-
tants of the cell culture were measured using a luciferin/luciferase assay (Mo-
lecular Probes) according to the manufacturer’s instruction.
High-Performance Liquid Chromatography Analysis of ATP, ADP,
AMP, and Adenosine in Human Primary B Cell Culture
To evaluate CD39 and CD73 enzymatic activity, B lymphocytes were isolated
by CD19 microbeads. Cells were then diluted in Hank’s solution (Sigma-
Aldrich) and plated at 105 cells/well in 96-well flat-bottom plates in the pres-
ence of the following stimuli: ATP (5 mM), ARL (100 mM), and CD73 inhibitor
(50 mM). At 0 and 40min after stimulation, cells were collected and centrifuged.
Supernatants were then collected and stored at 80C. Separation of adeno-
sine and its adenylic nucleotides (AMP, ADP, and ATP) was carried out by
reverse-phase high-performance liquid chromatography (HPLC) on an Agilent
1100 Series (Agilent Technologies), using an original method exploiting a
Kinetex C18 stationary phase (Phenomenex-Italia).
Time-Lapse TIRF Imaging
To measure vesicle localization, EBV-LCL cells were transfected using the
Amaxa Nucleofector technology, with complementary DNA plasmid encod-
ing for TI-VAMP-RFP and coincubated with mant-ATP for 12 hr or quinacrine
for a maximum of 60 min. To measure vesicle exocytosis, untransfected cells
were loaded with quinacrine for 60 min. To measure submembrane calcium,
cells were loaded with quinacrine and X-rhod for 60 min. Time-lapse imaging
was conducted using a Leica inverted microscope equipped with a 360
objective Plapon/TIRFM-SP1 oil immersion and diode solid-state lasers
(488 and 532 nm). The laser beam was tilted at a specific critical angle to
obtain total internal reflection at the glass-cell interface according to Snell’s
law. Quinacrine was measured together with TI-VAMP-RFP or X-rhod fluo-
rescence in sequential mode under evanescent field illumination. Fluores-
cence was measured in circular areas located in the soma and plotted
with time.
Statistical Analysis
Unpaired Student’s t test was used for statistical comparisons, and p values%
0.05 were considered significant.1830 Cell Reports 3, 1824–1831, June 27, 2013 ª2013 The AuthorsSUPPLEMENTAL INFORMATION
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Figure S1. Expression of CD39 andCD73 inMouse B Lymphocytes and Their Functional Characterization, Related to Results and Discussion
(A) CD39 andCD73 expression in mouse B lymphocyte subsets identified as follows: marginal zone B cells (MZ, CD19+B220+CD21+CD23), follicular B cells (FO,
CD19+B220+CD21+CD23+), isotype switch B cells (CD19+B220+IgMIgD) and germinal center B cells (GC, CD19+B220+Fas+PNA+) in the spleen, and naive B
cells (CD19+B220+IgM+IgD+), isotype switch B cells (CD19+B220+IgMIgD) and germinal center B cells (GC, CD19+B220+Fas+PNA+) in mLNs and PPs. CD73 is
expressed in a subset of CD39+ follicular (2.2% ± 0.3), marginal zone (8.6% ± 1.6) B cells, and in a larger fraction of CD39+ isotype switch B cells (24% ± 6.1) and
germinal center B cells (11.3% ± 1.6) in the spleen. In mLNs CD73 is expressed in a small subsets of CD39+ mature naive B cells (1.6% ± 0.4) as well as in PPs
(1.9% ± 0.3). Remarkably, CD73 ismore expressed in isotype switch B cells and GCB cells in mLNs (13% ± 1.8 and 26 ± 2.4 respectively) as well as in PPs (18.1 ±
3.1 and 16.9 ± 1.5, respectively), indicating that CD73 expression is mainly confined to antigen experienced B cell subsets. Bars show distribution of cells in the
indicated subset according to CD39 and CD73 expression, spleen, n = 5, LNs, n = 5 and PPs, n = 5.
(B) Naive nonswitch B cells (CD19+B220+IgGIgA) from LNs and PPs were sorted as CD39+CD73 and CD39+CD73+ B cells and then stimulated in vitro.
Frequency of IgG and IgA secreting cells measured by ELISPOT assay at day 4 after stimulation (LNs IgG ISC, CpG **p = 0.023, CpG, anti-Ig, anti-CD40 ***p =
0.0002; PPs IgG ISC, CpG *p = 0.0155, CpG, anti-Ig, anti-CD40 *p = 0.0172; PPs IgA ISC, CpG ***p = 0.0001, CpG, anti-Ig, anti-CD40 *p = 0.03).
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Figure S2. Human B Cell Proliferation of B Lymphocytes and Ca2+ Analysis, Related to Results and Discussion
(A) CFSE dilution in CD39+CD73 and CD39+CD73+ naive and IgMmemory B cells from healthy donors stimulated as indicated. Percentages of cycling cells are
shown.
(B) Wide-field Ca2+imaging. Isolated EBV-LCL (upper panels) and B cells (lower panels) were loaded with fura-2 for digital calcium imaging. Fluorochrome
excitation (340 and 380 nm) was achieved using a Xenon lamp in series with a filter wile. Emitted light was collected behind a band-pass filter by intensified CCD
camera. Images display the spatio-temporal changes of intracellular Ca2+ levels. Whole cell Ca2+ signal was measured before and after anti-ig stimulation as
indicated in the right graphics. Bar, 5 mm.
S2 Cell Reports 3, 1824–1831, June 27, 2013 ª2013 The Authors
CD39+CD73- 
CD39+CD73+
CD39+CD73- 
CD39+CD73+ 
0
2000
4000
6000
0
20
40
60
80
100
0
5
10
15
0.0
0.2
0.4
0.6
0
5
10
15
20
25
a.
u.
 
a.
u.
 
Pax5 Bcl6 
Aicda Prdm1 Xbp-1 
0
10
20
30
40
50
0
1
2
3
0
5
10
15
20
0
100
200
300
400
500
0
2000
4000
6000
8000
10000
Human IgM memory  B cells   
Pax5 Bcl6 
Aicda Prdm1 Xbp-1 
a.
u.
 
a.
u.
 * 
A
U
 
Adora2A (A2A) 
CD39+CD73- 
CD39+CD73+ 
naive IgM memory  0
200
400
600
800
A
U
 
Tlr9 
CD39+CD73- 
CD39+CD73+ 
Class switch  
memory 
IgM
Memory  
A B 
C 
0
2
4
6
Figure S3. Characterization of Gene Expression in Human BCell Subsets Isolated According to the Expression of CD39 and CD73, Related to
Results and Discussion
(A) ADORA2A expression was evaluated in resting CD39+CD73 and CD39+CD73+ naive as well as IgM memory B cells (n = 4).
(B) Tlr9 expression was measured in resting CD39+CD73 and CD39+CD73+ IgM memory B cells as well as class switch memory B cells (n = 4).
(C) Expression by RT-PCR of transcription factors involved in late B cell differentiation in resting naive and IgM memory B cells isolated according to the
expression of CD39 and CD73 (PAX5, n = 4; BCL6, n = 2-3, AICDA, n = 3-6, PRDM1, n = 2-3, XBP-1, n = 3 *p = 0.0470).
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Figure S4. Analysis of Surface Markers Expressed by Human B Cells Isolated According to the Expression of CD39 and CD73, Related to
Results and Discussion
Expression of costimulatory surface markers (CD80, CD86, HLADR, CD1d), TLR homolog RP105 (CD180), early activation markers (CD25, CD69) and survival
receptors (BAFFR, TACI) on naive and IgM memory B cells subsets identified by staining with mab to CD19, CD27, IgG and IgA in combination twith the specific
antibodies and isotype controls (n = 9-10, CD25 on naive *p = 0.0190 and onmemory *p = 0.0135; CD180 on naive *p = 0.027 and onmemory **p = 0.0023; BAFFR
on naive *p = 0.013 and on memory **p = 0.076; TACI on memory **p = 0.0021).
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Figure S5. Analysis of ATP Release and Class Switch Recombination in TI-VAMP-Deficient Mouse B Lymphocytes, Related to Results and
Discussion
(A) Increase in ATP release from mouse B lymphocytes isolated from WT LNs after in vitro stimulation with CpG 1826, anti-Ig, anti CD40, IL-21 and IL-2 (mean ±
SD, n = 6).
(B) Extracellular ATP concentrations in cultures of murine B lymphocytes isolated fromWT (circle) and Vamp7/ (square) LNs after in vitro stimulation with CpG
1826, anti-ig, anti CD40, IL-21 and IL-2.
(C) Relative decrease in IgG and IgA ISC in Vamp7 deficient mouse B lymphocytes (open bars) respect toWTB cells (close bars) after in vitro stimulation with CpG
1826 and IL21 or CpG 1826, anti-ig and IL-21. (LNs IgG, n = 2 CpG, IL-21 **p = 0.0085, CpG, anti-ig and IL-21 *p = 0.04; PPs IgG, n = 2-3 CpG, IL-21 *p = 0.03,
CpG, anti-ig and IL-21 ****p < 0.0001, PPs IgA, CpG, IL-21 p = 0.053, CpG, anti-ig and IL-21 *p = 0.034).
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Figure S6. Analysis of Class Switch Recombination in CD73-Deficient Mouse B Lymphocytes, Related to Results and Discussion
(A) Representative dot plots of CD73 expression and cell tracker dilution in naive B cells isolated from LNs and PPs after 5 days of stimulation with CpG and anti-Ig
with and without IL-21.
(B) Percentage of CD73 positive cells in LNs and PPs naive B cells after stimulation with CpG alone or in combination with anti-ig with or without IL-21 (n = 5, LNs,
CpG, anti-Ig *p = 0.0142, PPs, CpG, anti-ig *p = 0.0193).
(C) Relative decrease of IgG ISC in Nt5e deficient naive B cells isolated from LNs and PPs after 5 days of in vitro stimulation with CpG or CpG and anti-ig in the
presence of IL-21. (n = 3 LNs IgG, CpG, IL-21 **p = 0.0076, CpG, anti-ig and IL-21 **p = 0.0016, n = 3 PPs IgG CpG, IL-21 **p = 0.0098, CpG, anti-ig and IL-21 *p =
0.036).
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Figure S7. Percentage of CD39+CD73+ in Different Human Peripheral B Cell Subsets in Age-Matched Control and CVID Patients, Related to
Results and Discussion
Percentage of CD39+CD73+ and CD39+CD73 in peripheral B cell subsets, namely naive, IgM memory and switch memory in CVID patients compared with age
matched healthy donors (naive CD39+CD73+ CVID versus HD, **p = 0.022; IgM memory CD39+CD73+ CVID versus HD, **p = 0.0015; switch memory
CD39+CD73+ CVID versus HD, ****p < 0.0001).
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Figure S8. Analysis of Somatic Hypermutation and Class Switch Recombination in B Cells Isolated from CVID Patients, Related to Results
and Discussion
(A) Analysis of somatic mutations in a CVID patient and age-matched healthy donor (HD). Left graph shows the number of mutations per clone, right graph
displays the percentage of mutated IgHV rearrangments.
(B) Intracellular staining of CD73 in flow cytometry in age-matched HD (blue histogram) and a representative CVID patient (red line). Dotted line depicts staining
with isotype-matched antibody in HD.
(C) CFSE dilution and surface IgG/A expression in CD19+ B cells isolated from CVID patient (upper panel) and HD (lower panel) and stimulated with reciprocal
irradiated CD4+ T cells in the presence of a combination of bacterial superantigen TSST, CpG 2006 and anti-Ig. Percentages of cells within the quadrants are
shown.
(D) Percentage of CVID and HD IgG/A secreting cells in ELISPOT assay relative to total CD19+ cells at 5 days after stimulation as indicated.
(E) mRNA levels for AICDA and BCL6 were determined by quantitative real-time PCR and normalized to the amount of 18S.
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